| abstract |
The use of a compound of formula (II) wherein R1 is hydrogen or acetyl; R2 is hydrogen, -CH2O-C(O)C(CH3)3, C1-C4-alkyl, aryl, -(C1-C4-alkyl)-aryl, or diphenylmethyl; X is -(CH2)n wherein n is an integer 0 or 1, -S-, -O-, NR3 or N(CO)R4 wherein R3 is hydrogen, C1-C4-alkyl, aryl, or -(C1-C4-alkyl)-aryl; and R4 is CF3, C1-C10-alkyl, aryl, or -(C1-C4-alkyl)-aryl; B1 and B2 are each independently hydrogen, hydroxyl, or -OR5, wherein R5 is C1-C4-alkyl, aryl, or -(C1-C4-alkyl)-aryl or, where B1 and B2 are attached to adjacent carbon atoms, B1 and B2 can be taken together with said adjacent carbon atoms to form a benzene ring or methylenedioxy, or a pharmaceutically acceptable salt or stereoisomer thereof, for the manufacture of a medicament for inhibiting both angiotensin converting enzyme and neutral endopeptidase for treatment or prevention of a disease amenable to treatment with a compound that inhibits both angiotensin converting enzyme and neutral endopeptidase wherein the disase is selected from the group consisting of diabetic nephropathy, insulin resistance, diabetic neuropathy, diabetic retinopathy, myocardial infarction, cataracts, diabetic cardiomyopathy and non-diabetic nephropathy, is disclosed. |